Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.

Cancer Sci · 2022 · PMC9207363 · PMID 35377496

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Furthermore, using PSM, we found that the median PFS and OS of COMB showed a trend toward better than MONO, although they were not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.